2-[4-(4-Acetoxypiperidin-1-yl)benzyl]phenyl 2,3,4,6-tetra-O-benzoyl-7-deoxy-D-glycero-β-D-gluco-heptopyranoside | 1005487-13-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-[4-(4-Acetoxypiperidin-1-yl)benzyl]phenyl 2,3,4,6-tetra-O-benzoyl-7-deoxy-D-glycero-β-D-gluco-heptopyranoside
• 英文别名: [(2S,3R,4S,5R,6R)-2-[2-[[4-(4-acetyloxypiperidin-1-yl)phenyl]methyl]phenoxy]-3,5-dibenzoyloxy-6-[(1R)-1-benzoyloxyethyl]oxan-4-yl] benzoate
• CAS: 1005487-13-7
• 化学式: C₅₅H₅₁NO₁₂
• 分子量: 918.009
• InChiKey: RSKJKPUFZNGIRG-VPBKYMQRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  11.1
• 重原子数：
  68
• 可旋转键数：
  20
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  153
• 氢给体数：
  0
• 氢受体数：
  13

文献信息

• BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE
  申请人：Honda Takeshi

  公开号：US20090137499A1

  公开（公告）日：2009-05-28

  The present invention relates to a benzylphenyl glucopyranoside derivative having an excellent inhibitory effect on human SGLT1 and/or SGLT2 activity. There is provided a compound or a pharmacologically acceptable salt thereof represented by the following general formula (I): wherein R 1 represents a hydrogen atom, an amino group, a hydroxy C 1 -C 6 alkyl group, etc.; R 2 represents a hydrogen atom, etc.; R 3 represents a C 1 -C 6 alkyl group, a hydroxy C 1 -C 6 alkyl group, etc.; R 4 represents a hydrogen atom, a C 2 -C 7 acyl group, etc.; R 5 , R 6 , R 7 , and R 8 are the same or different and each represents a hydrogen atom or a C 1 -C 6 alkyl group, provided that R 5 , R 6 , R 7 and R 8 are not hydrogen atoms at the same time; n is 0 to 4; and X is CH or N.

  本发明涉及一种对人类SGLT1和/或SGLT2活性具有优异抑制作用的苯甲基苯基葡萄糖吡喃糖苷衍生物。提供了一种化合物或其药理学上可接受的盐，其代表以下通式（I）： 其中，R1代表氢原子，氨基，羟基C1-C6烷基等；R2代表氢原子等；R3代表C1-C6烷基，羟基C1-C6烷基等；R4代表氢原子，C2-C7酰基等；R5，R6，R7和R8相同或不同，每个代表氢原子或C1-C6烷基，但要求R5，R6，R7和R8同时不是氢原子；n为0到4；X为CH或N。
• BENZYL PHENYL GLUCOPYRANOSIDE DERIVATIVE
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP2048150A1

  公开（公告）日：2009-04-15

  The present invention relates to a benzylphenyl glucopyranoside derivative having an excellent inhibitory effect on human SGLT1 and/or SGLT2 activity. There is provided a compound or a pharmacologically acceptable salt thereof represented by the following general formula (I): wherein R1 represents a hydrogen atom, an amino group, a hydroxy C1-C6 alkyl group, etc.; R2 represents a hydrogen atom, etc.; R3 represents a C1-C6 alkyl group, a hydroxy C1-C6 alkyl group, etc.; R4 represents a hydrogen atom, a C2-C7 acyl group, etc.; R5, R6, R7, and R8 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, provided that R5, R6, R7 and R8 are not hydrogen atoms at the same time; n is 0 to 4; and X is CH or N.

  本发明涉及一种对人类 SGLT1 和/或 SGLT2 活性具有极佳抑制作用的苄基苯基吡喃葡萄糖苷衍生物。本发明提供了由以下通式（I）代表的化合物或其药理学上可接受的盐： 其中 R1 代表氢原子、氨基、羟基 C1-C6 烷基等；R2 代表氢原子等；R3 代表 C1-C6 烷基、羟基 C1-C6 烷基等；R4 代表氢原子、C2-C7酰基等；R5、R6、R7 和 R8 相同或不同，且各自代表氢原子或 C1-C6 烷基，但 R5、R6、R7 和 R8 不能同时为氢原子；n 为 0 至 4；X 为 CH 或 N。